LMEDD 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-20

• During the quarter ended March 31, 2026, the Company undertook a strategic transition toward the development of artificial intelligence-enabled healthcare technology solutions and related healthcare services infrastructure focused on Latin America.

• On February 17, 2026, the Company entered into an Asset Purchase Agreement pursuant to which it acquired certain proprietary healthcare technology assets and intellectual property relating to an artificial intelligence-enabled healthcare analytics platform and a technology-enabled healthcare service…

• In connection with the Company’s strategic transition, the Company also established and organized operations through its wholly-owned Venezuelan subsidiary, Inversiones Long 33, C.A., which is intended to serve as the Company’s operating entity in Venezuela and support its broader Latin American bus…

• During April 2026, certain intellectual property assets acquired by the Company were assigned to the subsidiary as part of an internal operational reorganization. Prior to such assignment, the subsidiary had no material operations, assets, liabilities, or standalone financial history.

• Current activities are focused on organizational development, operational structuring, technology evaluation, regulatory planning, and business development initiatives related to the Company’s intended healthcare technology platform and services model.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• Results of Operations for the three months ended September 30, 2025 and 2024

• We earned no revenues for three ended September 30, 2025 or 2024.

• We incurred $27,935 in operating expenses for the three months ended September 30, 2025, as compared with $33,668 in the three months ended September 30, 2024. The decrease in operating expenses is the result of the decrease in professional fees during the three months ended September 30, 2025. We e…

• We had other expenses of $8,367 for the three months ended September 30, 2025, compared to other expense of $9,813 for the three months ended September 30, 2023. The increase in other expenses was the result of interest expense incurred on additional debt incurred during the period.

• We recorded a net loss of $36,302 for the three months ended September 30, 2025, compared to a net loss $43,481 for the three months ended September 30, 2024. The decrease in net loss was associated with the factors discussed above.

相对上期新增的文字 · 来源:10-Q · 2026-05-20

• Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under …

• The Company has not made any change in our internal control over financial reporting during the period ended March 31, 2026.

相对上期删除的文字 · 来源:10-Q · 2025-11-14

• The Company’s management is responsible for establishing and maintaining adequate internal control over the Company’s financial reporting. The Company’s controls over financial reporting are designed under the supervision of the Company’s Principal Executive Officer and Principal Financial Officer t…

• Under the supervision and with the participation of our Principal Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated un…

• As of September 30, 2025, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our internal control over financial reporting, as defined in Rules 13a-15(f) or 15d-15(f) promulgated under the Securities Exc…

• The management including its Principal Executive Officer/Principal Financial Officer, does not expect that its disclosure controls and procedures, or its internal controls over financial reporting will prevent all error and all fraud. A control system no matter how well conceived and operated, can p…

• Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.